Ivacaftor (VX-770)
产品编号: DC4128
Featured
我们的合作伙伴:
中国地区超过5000个高品质化合物库存
应用领域
Ivacaftor是一种有效可口服的 CFTR 增效剂，靶向G551D-CFTR和F508del-CFTR的EC50分别为100 nM 和 25 nM。
| Cas No.: |
873054-44-5 |
| 名称: |
N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide |
| 别名: |
vx770 |
| SMILES: |
CC(C)(C)C1=CC(=C(C=C1NC(=O)C2=CNC3=CC=CC=C3C2=O)O)C(C)(C)C |
| 分子式: |
C24H28N2O3 |
| 分子量: |
392.49 |
| 纯度: |
|
| 保存条件: |
2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: |
|
| In Vivo: |
|
| In Vitro: |
|
| References: |
Description of Ivacaftor: Ivacaftor (VX-770) is an experimental drug candidate For the treatment of cystic fibrosis, currently under development by Vertex Pharmaceuticals and the Cystic Fibrosis Foundation. The drug is designed to be effective in patient |
| Kinase Assay: |
|
| Cell Assay: |
|
| Animal Administration: |
|
| References: |
|
MSDS
COA
| LOT NO. |
DOWNLOAD |
|
|
| 2018-0101 |
|
询盘
